Clinical Trials Logo

Clinical Trial Summary

This is a single-center, evaluator-blinded study in healthy adult human subjects. Single 24-hour application of sponsor(s) provided test products along with positive and negative controls will be kept in contact with the skin of subjects under occlusion for at least 24 hours (+ 2 hours). The study can be conducted in a single group. Safety will be assessed throughout the study by monitoring adverse events. The subject's back between the scapula and waist will be utilized as application sites. Application sites will be evaluated for scoring the reaction, namely, erythema, dryness, and wrinkles on a 0-4 point scale separately for each parameter and edema on another 0-4 points scale as per the Draize Scale after 30+5 minutes of patch removal, 24±2 hours and 168±2 hours after patch removal.


Clinical Trial Description

The objective of this study is to evaluate the dermatological safety of the test products by 24 Hours patch test under complete occlusion on healthy adult human subjects and adequate representation of varied skin types (Oily, Dry, Normal, and Combination). This is a single-center, evaluator-blinded study in healthy adult human subjects. Single 24-hour application of sponsor(s) provided test products along with positive and negative controls will be kept in contact with the skin of subjects under occlusion for at least 24 hours (+ 2 hours). The study can be conducted in a single group. Safety will be assessed throughout the study by monitoring adverse events. The subject's back i.e. between the scapula and waist will be utilized as application sites. 26 subjects with varied skin types (Oily, Dry, Normal, and Combination, preferably equal ratio) will be enrolled in the study to get 24 completed subjects at the end of study. The expected total study duration will be approximately 9 days from patch application day. The duration of this study will be 9 days from enrollment day. There are total of 3 visits in this study and one optional visit. - Visit 01: Screening, Enrollment, and Patch Application (Day 01) - Visit 02: Patch Removal after 24 hours of application & 30 + 5 min Irritation scoring upon patch removal (Day 02) - Visit 03: 24 (± 2) hours Irritation Scoring (Day 03) after patch removal - Visit 04: The subject will be contacted telephonically on Day 08 for any signs of irritation at the patch application site. Follow-up visit for reactions if any to confirm recovery (Optional, if deemed necessary) [Irritation scoring at 168±2 hours post-patch removal (Day 09)]. Application Sites (Back) will be evaluated for scoring the reaction, namely, erythema, dryness, wrinkles on a 0-4 point scale separately for each parameter and oedema on another 0-4 points scale as per the Draize Scale after 30 + 5 minutes of patch removal (Day 02), 24±2 hours (Day 03) and 168±2 hours (Day 09) after the patch removal. Scoring data will be updated in tabular format and mean irritation scoring will be obtained from irritation scores and the same will be included in the final Product Summary Report for all test products after completion of the study. Demographic characteristics and results of the study will be summarized. Any AEs will be summarized with a number and a percentage. Four parameters namely erythema, dryness, wrinkles and oedema will be scored separately on the irritation scoring sheet. Irritation scoring data will be updated in tabular format. Data of each subject that has completed the initial 03 study visits i.e. Day 01, Day 02, and Day 03 of the study will be considered for Mean Irritation Score Derivation. Mean Irritation Score (MIS) and standard deviation will be calculated using a standard statistical formula for each product. The Product irritancy level will be classified and reported based on the classification of Mean Irritation Score per sec#17.1. Standard deviation will be calculated to provide variability of data. For calculation of Mean Irritation Score of erythema, dryness and wrinkles the highest score will be taken. MIS = Total score (highest score from Erythema, dryness, wrinkles + Oedema) for each test product / Total no. of Subjects. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05642702
Study type Interventional
Source NovoBliss Research Pvt Ltd
Contact Maheshvari N Patel, M.Pharma
Phone 91-9909013236
Email maheshvari@novobliss.in
Status Not yet recruiting
Phase N/A
Start date December 5, 2022
Completion date December 20, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1